Newsletter | August 22, 2023

08.22.23 -- Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke



Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke

Developing new treatments for acute ischemic stroke that can quickly and safely intervene at the right place and time has been a challenging endeavor. Today, the situation is changing due to technological developments related to stroke and recent advances in RNA-based medicines.


Align CMC Strategy With Clinical Path Requirements And Timelines

Manufacturers must understand the challenges associated with creating a CMC strategy, and the expertise and resources needed to execute it, in today’s crowded and diverse market.

The Development, Scale-Up, And Manufacturing Of Semi-Solid Dosage Forms

Topical products, whether prescription dermatological drugs or over-the-counter lotions, creams, or gels, present unique challenges in terms of development and manufacturing.

Environmental Sustainability: Wastewater Incineration Reduction

Discover an approach to wastewater treatment that reduces the environmental impact of small molecules production and introduces advanced treatment methodologies to avoid wastewater incineration.

Solving The Analytics Bottleneck In Cell Line Development

Discover a fully automated, benchtop, walk-away system for accelerated and efficient cell culture sample preparation. Learn how this system clarifies and purifies mAbs in one step without sacrificing quality.


CAS And Announce A Strategic Collaboration To Accelerate Drug Discovery

Parexel & Partex Announce Innovative Alliance Leveraging Artificial Intelligence & Big Data

Fluree Announces Partnership With Vitality TechNet

Artiva Biotherapeutics Announces FDA Clearance Of IND For AlloNK

FDA Accepts MyMD Pharmaceuticals’ IND For Phase 2 Study Of Oral TNF-α Inhibitor MYMD-1

Impilo Launches To Enable Nucleic Acid-Based Meds To Effectively Treat Solid Tumor Cancers

Avidity Biosciences Receives FDA ODD For AOC 1044

Tiny Antibodies Hold Big Promise For Cancer Treatment

City Of Hope Scientists Uncover New Active Regions On Cell Surface Receptor

Seagen Phase 3 Trial Of TUKYSA (Tucatinib) In Combination With Antibody-Drug Conjugate Ado-Trastuzumab Emtansine Meets Primary Endpoint Of PFS


Can You Run Crude Samples Using An SPR Instrument?

Cleanroom Capabilities And Expertise


Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.